TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05199064

Intervention type: OTHER
Intervention: Ultrasound guided greater occipital nerve (GON) radiofrequency
Description: After identifying the GON with ultrasound guidance, a catheter needle (22-gauge 5 cm 5 mm active tip hybrid electrode) is inserted with an in-plane technique from lateral to medial.After visualizing the electrode tip placed close to the right or left GON, a sensory stimulation test is performed using an RF generator (URF-3AP Diros Tecnology Inc.). After the patient reports dysesthesia and a tingling sensation at the occipital area with less than 0.2 V, the PRF treatment is administered at 5 Hz and 5 milliseconds pulsed width for 360 seconds at 45 V under the constraint that the temperature of the electrode tips does not exceed 42°C
Study: NCT00720811

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: malaria rapid diagnostic test, respiratory rate timer
Description: malaria dipstick, and breath timer

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Artemether-lumefantrine combination
Description: 20/120mg tablet arthermether-lumefantrine 4-35months: 1x2; 36-59months: 2x2
Study: NCT03983070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seated Rowing Ergometer
Description: Seated rowing exercise performed at a specific percentage of maximal Watts according to pre-intervention measures

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Seated Rowing Ergometer
Description: Seated rowing exercise performed at a specific percentage of maximal Watts according to pre-intervention measures

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deadlift
Description: Deadlift exercise performed with a set of dumbbell weights at a sepcific percentage of pre-intervention one-repetition maximum.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deadlift
Description: Deadlift exercise performed with a set of dumbbell weights at a sepcific percentage of pre-intervention one-repetition maximum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction
Description: An occlusive cuff will be placed around each proximal thigh and inflated to 80% arterial occlusion during exercise sessions.
Study: NCT03255590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Configuration task
Description: Training the impaired hand on a configuration task
Study: NCT01111487

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Expiratory positive airway pressure (EPAP) by face mask.
Description: Implementation of the EPAP as group pressure, 10 or 15 cmH2O, for 20 minutes then evaluated the electromyographic activity of muscles and sternocleidomastoid parasternal the tenth and twentieth minutes of your application.
Study: NCT03221530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Intervention for Suicide Risk Among Immigrant Youth
Description: The EISR-I intervention includes family treatment engagement, shared problem definition, and sessions designed to address family cohesion, communication, and conflict resolution.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: This intervention includes a session with the family to engage in safety planning and provide feedback on their baseline assessment data.
Study: NCT03701945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: Pulmonary rehabilitation will be provided to patients presenting an acute exacerbation. The intervention will be composed of exercise training, education and psychosocial support.
Study: NCT00241020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Study: NCT03342846

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: the first group received 20 Hz and the 2nd group received 1 Hz rTMS daily for 10 days 5 sessions every week on M1.
Study: NCT01447511

Intervention type: DRUG
Group type: OTHER
Intervention: Control - Warfarin only
Description: A single 10 mg warfarin dose taken at the start of the study period. No other medications taken during this study period.

Intervention type: DRUG
Group type: OTHER
Intervention: Control - Warfarin only
Description: A single 10 mg warfarin dose taken at the start of the study period. No other medications taken during this study period.
Study: NCT01953354

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trichuris suis ova (TSO)
Description: Six doses of TSO orally over a ten-week period (e.g., every 2 weeks x 10 weeks for a total of 6 total doses)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Six doses of TSO placebo orally over a ten-week period (e.g., every 2 weeks x 10 weeks for a total of 6 total doses)
Study: NCT03204747

Intervention type: OTHER
Intervention: Observational study : gait speed
Description: No intervention, only propose water and wait for need to void
Study: NCT01447511

Intervention type: DRUG
Group type: OTHER
Intervention: Control - Warfarin only
Description: A single 10 mg warfarin dose taken at the start of the study period. No other medications taken during this study period.

Intervention type: DRUG
Group type: OTHER
Intervention: Control - Warfarin only
Description: A single 10 mg warfarin dose taken at the start of the study period. No other medications taken during this study period.

Intervention type: DRUG
Group type: OTHER
Intervention: Control - Warfarin only
Description: A single 10 mg warfarin dose taken at the start of the study period. No other medications taken during this study period.

Intervention type: DRUG
Group type: OTHER
Intervention: Fluconazole - Warfarin
Description: A single 10 mg warfarin dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.

Intervention type: DRUG
Group type: OTHER
Intervention: Fluconazole - Warfarin
Description: A single 10 mg warfarin dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.

Intervention type: DRUG
Group type: OTHER
Intervention: Fluconazole - Warfarin
Description: A single 10 mg warfarin dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.

Intervention type: DRUG
Group type: OTHER
Intervention: Fluconazole - Warfarin
Description: A single 10 mg warfarin dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
Study: NCT01209832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasisulam
Description: Patient specific dose, administered intravenously, on Day 1 of a 28-day cycle. Minimum of one (1) 28-day cycle. Patients may continue to receive tasisulam until disease progression or until discontinuation criteria are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 1.2 milligrams (mg), administered orally once prior to the initiation of tasisulam therapy and once on Day 8 after initiation of tasisulam therapy
Study: NCT03722290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral administration of metformin 250mg (twice a day) for the 1st week followed by metformin 500mg (twice a day) for the next 8 weeks.
Study: NCT04763876

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Injection 15 mg
Description: A single dose of 15 mg ketorolac administered intramuscularly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Injection 60 mg
Description: A single dose of 60 mg ketorolac administered intramuscularly.
Study: NCT01155479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant 2 mg tablet
Description: Preladenant 2 mg oral tablet taken twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Preladenant 5 mg tablet
Description: Preladenant 5 mg oral tablet taken twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant 5 mg tablet
Description: Preladenant 5 mg oral tablet taken twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant 10 mg tablet
Description: Preladenant 10 mg oral tablet taken twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rasagiline 1 mg capsule
Description: Rasagiline 1 mg oral capsule taken once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Rasagiline 1 mg capsule
Description: Placebo for rasagiline 1 mg oral capsule taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Rasagiline 1 mg capsule
Description: Placebo for rasagiline 1 mg oral capsule taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Rasagiline 1 mg capsule
Description: Placebo for rasagiline 1 mg oral capsule taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Rasagiline 1 mg capsule
Description: Placebo for rasagiline 1 mg oral capsule taken once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Preladenant
Description: Placebo for preladenant 2 mg, 5 mg, or 10 mg oral tablet taken twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Preladenant
Description: Placebo for preladenant 2 mg, 5 mg, or 10 mg oral tablet taken twice daily
Study: NCT02034136

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginsenoside
Description: 3.0 g/ d for 28 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary fiber fill
Description: 3g/day, 28days
Study: NCT00733889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab and chemotherapy (docetaxel, cisplatin, 5-fluorouracil)
Description: Neoadjuvant chemotherapy plus cetuximab:~3 cycles of chemotherapy (Docetaxel: 75 mg/m2; day1; Cisplatin :75 mg/m2, day 1; 5-FU: 750 mg/m2; 24-hour infusion; day1-5) administered every 3 weeks, plus cetuximab (250 mg/m2; day 1, 8 and 15) Cetuximab will be maintained from the beginning of chemotherapy until the end of radiotherapy.~Radio-chemotherapy plus cetuximab:~The radiotherapy treatment: A dose of 50.4 Gy will be administered in 28 fractions of 1.8 Gy / day, 5 days a week (a total of 5.6 weeks).~Cetuximab:250 mg/m2 and Cisplatin: 40 mg/m2, day 1, 8, 15, 22, 29 and 36
Study: NCT00084773

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT00353028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine maleate
Description: Test product: Fluvoxamine maleate 25mg tablet. In case that the daily dose is one tablet, the study medication will orally be administered once daily, at bedtime. In case that the daily dose is two tablets or higher (maximam:6 tablets), the study mmedica

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03566836

Intervention type: DEVICE
Intervention: Garmin Smart Watch
Description: Garmin Smart Watch

Intervention type: DEVICE
Intervention: Garmin Chest Band
Description: Garmin Chest Band
Study: NCT01680133

Intervention type: OTHER
Intervention: Hyperinsulinemic euglycemic clamp

Intervention type: OTHER
Intervention: Hyperinsulinemic euglycemic clamp
Study: NCT00534469

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Study: NCT02577276

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tele-motion rehabilitation system
Description: Tele-motion rehabilitation system: Interventions include functional therapeutic exercise and real-time feedback. Clinicians remotely monitor subjects' motor performance using Microsoft Kinect 3D sensor tracking system in their home to record their upper limb and trunk movements as they participate in a variety of functional tasks and motor activities, which are directed by their interaction with a monitor screen in their home using uniquely adapted software to integrate key rehabilitation intervention principles.
Study: NCT03630276

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP
Description: Lab

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP
Description: Lab

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP
Description: Lab
Study: NCT02103543

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Description: physical therapy consisting of core strengthening, low back stretching and range of motion 3 sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Description: physical therapy consisting of core strengthening, low back stretching and range of motion 3 sessions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lumbar interlaminar epidural steroid injection
Description: single lumbar interlaminar epidural steroid injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lumbar interlaminar epidural steroid injection
Description: single lumbar interlaminar epidural steroid injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidural steroid injection
Description: Dexamethasone 10mg or Depomedrol 40mg, together with Bupivacaine 0.25% (for 3-5mL total injectate volume)
Study: NCT03978208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATB-346 low dose
Description: Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
Study: NCT01447511

Intervention type: DRUG
Group type: OTHER
Intervention: Rifampin - Warfarin
Description: A single 10 mg warfarin dose taken at the start of the study period. 300 mg rifampin taken every morning starting a week before the start of the study period and continuing throughout the study period.

Intervention type: DRUG
Group type: OTHER
Intervention: Rifampin - Warfarin
Description: A single 10 mg warfarin dose taken at the start of the study period. 300 mg rifampin taken every morning starting a week before the start of the study period and continuing throughout the study period.

Intervention type: DRUG
Group type: OTHER
Intervention: Rifampin - Warfarin
Description: A single 10 mg warfarin dose taken at the start of the study period. 300 mg rifampin taken every morning starting a week before the start of the study period and continuing throughout the study period.

Intervention type: DRUG
Group type: OTHER
Intervention: Rifampin - Warfarin
Description: A single 10 mg warfarin dose taken at the start of the study period. 300 mg rifampin taken every morning starting a week before the start of the study period and continuing throughout the study period.

Intervention type: DRUG
Group type: OTHER
Intervention: Rifampin - Warfarin
Description: A single 10 mg warfarin dose taken at the start of the study period. 300 mg rifampin taken every morning starting a week before the start of the study period and continuing throughout the study period.
Study: NCT01501448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel and ethinylestradiol
Description: 30 microgram of ethinylestradiol plus levonorgestrel daily for 12 to 16 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol valerate
Description: 4mg estradiol valerate from cycle day 20 till the day before the initiation of the cycle
Study: NCT04218435

Intervention type: DRUG
Intervention: Sacubitril / Valsartan Oral Tablet
Description: Sacubitril/Valsartan is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.~Sacubitril/Valsartan is usually administered in conjunction with another heart failure therapies, in place of an ACE inhibitor or other ARB.
Study: NCT04603703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HVLAT Manipulation
Description: Ultrasound for 10 mins/1 set/ (3 days/ week), Moist hot pack for 10 mins/1 set/ (3 days/ week), Piriformis stretching for 7 sec hold/ 7 repititions/ 1 set/ (3 days/ week), Myofascial release of lumbosacral paraspinal muscles for 3 mins/ 1 set/ (3 days/ week), Gluteal muscles strengthening for 10 sec hold/ 5 reps/ 1 set/ (3 days/ week), Sciatic Neurodynamics with 10 oscillations/ 3 sets/(3 days/ week), HVLAT manipulation/ 1 rep/ 1set/ (3 days/ week),~A total of 2 weeks (6 sessions, 3 sessions/ week) were given each consisting of 30 mins.
Study: NCT02103543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidural steroid injection
Description: Dexamethasone 10mg or Depomedrol 40mg, together with Bupivacaine 0.25% (for 3-5mL total injectate volume)
Study: NCT03583242

Intervention type: DRUG
Intervention: Antiangiogenic Agents
Description: 3 Intravitreal injections of 0.05 ml of Aflibercept (40 mg/ml) during 3 months (one per month) The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.

Intervention type: DRUG
Intervention: Corticosteroid
Description: 1 Injection of dexamethasone intravitreal implant 0.7mg. The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.
Study: NCT04562337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1316
Description: Anti-PD-L1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
Study: NCT01360775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutritional counseling
Description: Nutritional counseling to caregivers of dependant patients at nutritional risk, Who were participants in the Home Care program conducted by nurses
Study: NCT00590837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Induction: chemotherapy + lomustine (CCNU), 200 mg/m2 orally at day 1.~Consolidation: chemotherapy + lomustine (CCNU), 80 mg orally at day 1.~Reinductions: chemotherapy + lomustine (CCNU), 40 mg orally at day 1.
Study: NCT04562337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Thoracic radiation therapy ,TRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
Study: NCT01215630

Intervention type: BEHAVIORAL
Intervention: Aerobic Interval Training
Description: One interval training session
Study: NCT04603703

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Ultrasound for 10 mins/1 set/ (3 days/ week), Moist hot pack for 10 mins/1 set/ (3 days/ week), Piriformis stretching for 7 sec hold/ 7 repititions/ 1 set/ (3 days/ week), Myofascial release of lumbosacral paraspinal muscles for 3 mins/ 1 set/ (3 days/ week), Gluteal muscles strengthening for 10 sec hold/ 5 reps/ 1 set/ (3 days/ week), Sciatic Neurodynamics with 10 oscillations/ 3 sets/(3 days/ week),~A total of 2 weeks (6 sessions, 3 sessions/ week) were given each consisting of 30 mins.
Study: NCT04237415

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EMG biofeedback training
Study: NCT03978208

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATB-346 mid-dose
Description: Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATB-346 standard dose
Description: Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
Study: NCT01766843

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide Diskus and charcoal
Description: 2 inhalations as a single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide Diskus
Description: 2 inhalations as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SF Easyhaler and charcoal
Description: 2 inhalations as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SF Easyhaler
Description: 2 inhalations as a single dose
Study: NCT04057638

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Craniomaxillofacial and Upper Extremity Allotransplantation
Description: Combined Craniomaxillofacial and Upper Extremity Allotransplantation
Study: NCT02309710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ShangRing
Description: ShangRing administered to males seeking medical male circumcision
Study: NCT03946306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5,25% NaOCl with syringe needle irrigation alone
Description: In group 1 (control group), a final irrigation will be made with 1.5 ml of NaOCl per canal, during 30 seconds in an up-and-down motion, with the needle 1 mm short of the working length, without binding. After this, a 30 seconds pause will be done. This step will be repeated once again.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EDDY
Description: In group 2, a final irrigation will be made with 1.5 ml of NaOCl per canal and the irrigant will be activated using EDDY tips, 1 mm short of the working length without binding. The activation will be performed during 30 seconds, followed by a 30 seconds pause, and the cycle will be repeated once again, according to manufacture instructions.